title: Monoclonal antibodies for medical oncology: a few critical perspectives.
abstract: Incorporation of antibodies as weapons for cancer therapy has meant a turning point in the survival, clinical and radiological response of many oncology patients. These drugs are effective, well designed missiles that either alone or in combination with chemotherapy are unavoidable weapons for breast, lung and colon cancer as well as for haematological tumours. In addition, incoming monoclonal antibodies (mAbs) and folder-like proteins will be incorporated into clinical practice in the near future. This review aims to discuss a few imminent indications of current mAbs that are used for solid tumours and to briefly introduce future mAbs to the reader.
authors.affiliation: Biomarkers and Experimental Therapeutics Group, IdiPAZ, University Hospital La Paz, Madrid, Spain. cbelda.hulp@salud.madrid.org
authors.forename: Cristóbal
authors.initials: C
authors.lastname: Belda-Iniesta
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Ibáñez de Cáceres
authors.forename: Javier
authors.initials: J
authors.lastname: de Castro
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D008495:Medical Oncology / Q000379:methods / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents